Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Lipoprotein(a): A Risk Factor and Biomarker in Heart Failure
Author(s): Anna Kowalczys , Joanna Marlęga-Linert , Marcin Gruchała , et al Added: 1 month ago

Imaging & Diagnostics

Prevention & Chronic Conditions
TAVR is Ready for Most Low-risk Patients
Author(s): Ahmad Jabri , Anas Alameh , Gennaro Giustino , et al Added: 1 year ago

Intervention

Vascular Disease and Surgery
Metabolic Factors Now Key Drivers of Heart Failure
Added: 5 months ago Source:  Radcliffe Cardiology
The primary drivers of heart failure (HF) have shifted significantly over the past 35 years, with metabolic conditions such as obesity and diabetes now playing a more prominent role than traditional risk factors like myocardial infarction (MI).¹˒² This finding comes from a large US-based study analysing national health trends.MethodologyResearchers conducted a retrospective analysis of data from… View more

MI/ACS

Prevention & Chronic Conditions
Polygenic Risk Score Independently Predicts New-Onset Heart Failure
Added: 9 months ago Source:  Radcliffe Cardiology, Mirjam Boros
The global burden of heart failure (HF) remains a significant challenge for healthcare systems.² While clinical risk factors are well-established, the utility of genetic information in predicting incident HF has been less certain. A recent study investigated the ability of a heart failure polygenic risk score (HF PRS) to predict new-onset HF in individuals across the full spectrum of… View more

Imaging & Diagnostics

Prevention & Chronic Conditions
EASD 25: EMPIRE-PREVENT: Metabolic Effects of Empagliflozin in Patients at Risk of Heart Failure
Author(s): Camilla Andersen Added: 8 months ago
EASD Congress 2025 - Dr Camilla Andersen (The University of Western Australia, Perth, AU) joins us to discuss findings from the EMPIRE-PREVENT: Metabolic study, investigating the metabolic effects of empagliflozin in elderly and obese patients at high risk of developing heart failure (HF).This randomized controlled trial evaluated 165 patients aged 60–84 years with obesity (BMI >28kg/m²) and… View more

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
Added: 11 months ago Source:  Radcliffe CVRM
AUTHOR: Liam ONeillWhile elevated systolic blood pressure variability (SBPV) is a known risk factor for adverse health outcomes, new research published in the European Heart Journal suggests that the change in SBPV over time is also a critical prognostic indicator. The study found that an increase in visit-to-visit SBPV over a 10-year period was significantly associated with a higher risk of… View more

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
Heart Disease in Pregnancy: Maternal and Neonatal Risk
Author(s): Rofila Dita Karmia , Mefri Yanni , Yusrawati , et al Added: 5 months ago

Inherited and Congenital Cardiac Conditions

Electrophysiology & Arrhythmia
EASD 2025 Highlights: Updates on Icosapent Ethyl and Cardiometabolic Risk
Author(s): Rahul Aggarwal , Dirk Müller-Wieland Added: 8 months ago
Filmed onsite at EASD 2025, this on-demand series features key insights from Prof Dirk Müller-Wieland and Dr Rahul Aggarwal to interpret the latest data on eicosapentaenoic acid(EPA), including the latest sub-analysis of the REDUCE-IT trial, whichanalysed the effectiveness of icosapent ethyl (IPE) on CV risk by triglyceride-glucose (TyG) index - an indicator of insulin resistance and risk of type… View more

Heart Failure

Prevention & Chronic Conditions
ESCHFA25: FINEARTS-HF: Finerenone Risk-Benefit Across Kidney Function
Author(s): Safia Chatur Added: 1 year ago
ESC HF 25 - In a FINEARTS HF post-hoc analysis, the relative and absolute effects of finerenone relative to placebo did not significantly differ across kidney function.We are joined by Dr Safia Chatur (Mass General Cardiology, US) to discuss key findings from the FINEARTS-HF trial. This Phase 3 study evaluated the effect of finerenone versus placebo on cardiovascular death and total heart failure… View more

Cardiovascular Kidney Metabolic

Heart Failure
Social Factors Impact Outcomes in HCM Patients
Added: 5 months ago Source:  Radcliffe Cardiology
While social determinants of health (SDOH) are known to influence outcomes in acquired cardiovascular diseases, their impact on conditions with a strong genetic basis, such as hypertrophic cardiomyopathy (HCM), has been less clear.² A new study using data from the Sarcomeric Human Cardiomyopathy Registry (SHaRe) suggests that area-based social factors are independently associated with adverse… View more

Prevention & Chronic Conditions

Electrophysiology & Arrhythmia